Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
1.79M
-
Number of holders
-
29
-
Total 13F shares, excl. options
-
494K
-
Shares change
-
+494K
-
Total reported value, excl. options
-
$4.42M
-
Value change
-
+$4.42M
-
Number of buys
-
28
-
Price
-
$8.96
Significant Holders of Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) as of Q2 2025
29 filings reported holding LYRA - Lyra Therapeutics, Inc. - Common Stock, $0.001 par value as of Q2 2025.
Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) has 29 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 494K shares
of 1.79M outstanding shares and own 27.62% of the company stock.
Largest 10 shareholders include PERCEPTIVE ADVISORS LLC (255K shares), SABBY MANAGEMENT, LLC (126K shares), VANGUARD GROUP INC (29.2K shares), BANK OF AMERICA CORP /DE/ (28.5K shares), Ikarian Capital, LLC (21.2K shares), GEODE CAPITAL MANAGEMENT, LLC (11K shares), STATE OF WISCONSIN INVESTMENT BOARD (10.5K shares), MORGAN STANLEY (2.16K shares), FMR LLC (1.75K shares), and BlackRock, Inc. (1.69K shares).
This table shows the top 29 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.